Less Ads, More Data, More Tools Register for FREE

Pin to quick picksXaar Regulatory News (XAR)

Share Price Information for Xaar (XAR)

Share Price is delayed by 15 minutes
Get Live Data
145.00    3.00 (2.11%)
Bid:
140.50
Ask:
144.50
Spread: 4.00 (2.847%)
Market Cap: £113.79m
XAR Live PriceLast checked at - London Stock Exchange

Intraday Xaar Share Chart

Trading Statement

20 Nov 2017 07:00

RNS Number : 9048W
Xaar PLC
20 November 2017
 

Xaar plc

 

Trading Update

 

Xaar plc ("Xaar"), a world leader in industrial inkjet technology, provides a trading update today.

 

Further to our interim results statement in September and our earlier trading update in July, in which we indicated that growth in revenues from new products was expected to be second half weighted, the board now expects that revenue in the second half year will be broadly in line with the first half. The shortfall against previous expectations results largely from fewer than planned new printer installs of Xaar's 2001 Printhead, and slower than anticipated ramp up of the Xaar 1201 Printhead due to supply constraints.

In ceramics, the printhead replacement business is now anticipated to represent c.70% of revenues in 2017. The new 1003 Printhead has performed strongly in this market but as competition for new printer installs continues to intensify, we have seen more limited success with the 2001 product.

Demand for the 1201 Printhead remains strong, but due to supply constraints, we have not been able to fulfil all of the demand this year. We expect supply will improve with new capacity coming on stream next year, and we continue to expect significant growth in 2018.

Although disappointed by the revenue shortfall on the underlying business, we are encouraged by our reducing dependence on our legacy ceramics business, where there is little visibility, and increasing competitive pressure. Our 2020 vision and commitment to delivering growth from new products in new markets is undiminished but the timing of ramp up of the range of new products we have introduced remains less predictable. In 2017 we expect that 80% of our underlying revenues will be from the seven new products introduced and new businesses acquired in the last two years. This progress, together with our previously announced increased investment in sales and marketing, supports our continuing transformation to a more diversified and customer-centric company.

 

Enquiries:

 

Xaar plc

 

Doug Edwards, Chief Executive Officer

Lily Liu, Chief Financial Officer

 

+44 (0)1223 423 663 

Tulchan Communications

James Macey White

David Ison

Deborah Roney

+44 (0)20 7353 4200

 

About Xaar

Xaar is a world-leader in the development of inkjet technology and manufacture of piezoelectric drop-on-demand industrial printheads. The company also develops and sells ink systems, electronics and fluid optimisation services to accelerate inkjet system development and adoption. Xaar printheads incorporate patented technology, which delivers unbeatable performance when decorating, patterning, depositing functional coatings on, or adding structure to, a variety of industrial and consumer products. Today leading manufacturers worldwide, in sectors ranging from ceramics, wide-format graphics and labels to direct-to-shape packaging and decorative laminates, choose Xaar's printheads because they are extremely precise, exceptionally versatile, incredibly reliable, and designed for high-volume production. Additional information about Xaar is available at www.xaar.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTVKLFFDFFZFBF
Date   Source Headline
2nd Jun 202612:58 pmRNSTotal Voting Rights
28th May 20269:18 amRNSResult of AGM
6th May 20267:00 amRNSDirector/PDMR Shareholding
5th May 202611:36 amRNSHolding(s) in Company
30th Apr 20264:44 pmRNSHolding(s) in Company
16th Apr 20269:00 amRNSPublication of Annual Report and Notice of AGM
1st Apr 20263:43 pmRNSHolding(s) in Company
24th Mar 20267:05 amRNSFinal Results
23rd Mar 20263:33 pmRNS-RInvestor Presentation via Investor Meet Company
2nd Mar 20262:44 pmRNSTotal Voting Rights
14th Jan 20267:00 amRNSTrading Statement
5th Jan 202612:28 pmRNSTotal Voting Rights
5th Dec 20251:15 pmRNSHolding(s) in Company
1st Dec 202512:15 pmRNSTotal Voting Rights
24th Nov 202511:00 amRNSDirector/PDMR Shareholding
3rd Nov 20252:00 pmRNSTotal Voting Rights
21st Oct 20254:15 pmRNSDirector/PDMR Shareholding
13th Oct 20253:20 pmRNSHolding(s) in Company
2nd Oct 202511:10 amRNSDirector/PDMR Shareholding
2nd Oct 20258:50 amRNSDirector/PDMR Shareholding
1st Oct 20255:00 pmRNSDirector/PDMR Shareholding
1st Oct 20253:30 pmRNSTotal Voting Rights
1st Oct 202512:04 pmRNSTRADING UPDATE and NOTICE OF RESULTS
1st Sep 20254:30 pmRNSTotal Voting Rights
12th Aug 20257:00 amRNS2025 INTERIM RESULTS
5th Aug 20257:00 amRNSBoard changes
1st Aug 20253:45 pmRNSTotal Voting Rights
14th Jul 202510:00 amRNSNotice of Interim Results
7th Jul 20253:30 pmRNSBlock listing Interim Review
2nd Jul 20253:30 pmRNSTotal Voting Rights
30th Jun 20252:00 pmRNSDirector/PDMR Shareholding
3rd Jun 202510:00 amRNSTotal Voting Rights
28th May 20253:30 pmRNSResult of AGM
21st May 20251:00 pmRNSHolding(s) in Company
7th May 20253:30 pmRNSNotification of Transactions of Directors & PDMRs
2nd May 202510:30 amRNSTotal Voting Rights
15th Apr 20251:15 pmRNS2024 Annual Report and Notice of AGM
11th Apr 202512:00 pmRNSHolding(s) in Company
1st Apr 20254:15 pmRNSHolding(s) in Company
1st Apr 20253:30 pmRNSTotal Voting Rights
31st Mar 20253:45 pmRNSNotification of Transactions of Directors & PDMRs
31st Mar 20251:10 pmRNSHolding(s) in Company
28th Mar 202511:30 amRNSHolding(s) in Company
27th Mar 202511:00 amRNSHolding(s) in Company
25th Mar 20255:00 pmRNSNotification of Transactions of Directors & PDMRs
25th Mar 20257:00 amRNSFinal Results
5th Mar 202511:30 amRNSTotal Voting Rights
19th Feb 202510:30 amRNSHolding(s) in Company
10th Feb 202511:00 amRNSHolding(s) in Company
5th Feb 20254:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.